• 1
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 2
    Thomas E, Hay EM, Hajeer A, Silman AJ. Sjögren's syndrome: a community-based study of the prevalence and impact. Br J Rheumatol 1998; 37: 106976.
  • 3
    Hochberg MC, Spector TD. Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 1990; 12: 24752.
  • 4
    Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol 1985; 24: 14754.
  • 5
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 48194.
  • 6
    Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus: results from a single center. III. Improved survival over 24 years. J Rheumatol 1997; 24: 10615.
  • 7
    Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 7505.
  • 8
    Martens PB, Pillemer SR, Jacobsson LTH, O'Fallon MW, Matteson EL. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999; 26: 1296300.
  • 9
    Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001; 60: 46772.
  • 10
    Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000; 29: 296304.
  • 11
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002; 46: 7417.
  • 12
    Manthorpe R, Oxholm P, Prause JU, Schiodt M. The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol 1986; 15 Suppl 61: 1921.
  • 13
    Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al, the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 3407.
  • 14
    Greenspan JS, Path MRC, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg 1974; 37: 21729.
  • 15
    Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R, et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between Sjögren's syndrome and hepatitis C in Swedish patients. J Intern Med 1999; 245: 12732.
  • 16
    Davidson BKS, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 1999; 38: 24553.
  • 17
    Jonsson R, Kroneld U, Backman K, Magnusson B, Tarkovski A. Progression of sialadenitis in Sjögren's syndrome. Br J Rheumatol 1993; 32: 57881.
  • 18
    Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R, et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients: can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 2000; 59: 5460.
  • 19
    Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 106570.
  • 20
    Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996; 39: 76772.
  • 21
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, and the members of the European Concerted Action on Sjögren's syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42: 176572.
  • 22
    Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 88892.
  • 23
    Janin A, Morel P, Quiquandon I, Farre I, Hatron PY, Bauters F, et al. Non-Hodgkins' lymphoma and Sjögren's syndrome: an immunopathological study of 113 patients. Clin Exp Rheumatol 1992; 10: 56570.
  • 24
    Pariente D, Anaya JM, Combe B, Jorgensen C, Emberger JM, Rossi JF, et al. Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med 1992; 1: 33742.
  • 25
    Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997; 8: 2014.
  • 26
    Ramos-Casals M, Garcia-Carrasco M, Cervera R, Filella X, Trejo O, de la Red G, et al. Th1/Th2 cytokine imbalance in patients with Sjögren's syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 5663.
  • 27
    De Vita S, Damato R, de Marchi G, Sacco S, Ferraccioli G. True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. Isr Med Assoc J 2002; 4: 11015.
  • 28
    Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson LT. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000; 29: 208.